TAMPA, FL - March 09, 2026 - PRESSADVANTAGE - WhiteSands Treatment Center has published a new educational resource ...

Otsuka Pharmaceutical Co. Ltd. filed an NDA with the U.S. FDA for centanafadine (formerly EB-1020), a new nonstimulant therapy for treating attention-deficit hyperactivity disorder (ADHD) in children, ...

Medically reviewed by Patricia Mikula, PharmD Key Takeaways ADHD is often treated with medications and behavioral therapy. Stimulants are first-choice medications for children with ADHD. ADHD symptoms ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved the treatment for patients with ADHD aged 6 years and older. Onyda XR is the first and only ...

A large sample size of high school seniors also meant researchers could separate doctor-prescribed ADHD medication use by gender. The results show no gender differences in the overall associations ...